EC approves CSL’s Andembry to stop hereditary angioedema attacks
CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...
pharmaphorum17h
EU approves CSL's once-monthly HAE drug Andembry
CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...
PMLiVE19h
EC approves CSL’s Andembry to prevent hereditary angioedema attacks
The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...